As above reported, many are the hematological contexts where ddPCR has been used and implemented: acute leukemias, where it is able to quantitate NPM1 mutations but also WT1 expression; Ph’-positive leukemias, where it is used for measuring more accurately the BCR-ABL1/ABL1 ratio to also identify the patients best candidate to TFR but also for BCR-ABL1 mutations detection; the MPNs, where JAK2 and CALR mutations have a clear diagnostic role, and the lymphoma/myeloma setting, where IgH and TCR clonality can be combined with BCL2/JH and BCL1/JH fusion genes for assessing MRD. Here, BCL2 is linked to lymphoma.